A phase I study of combination therapy with WT1 peptide-pulsed dendritic cells and gemcitabine for advanced pancreatic and biliary tumors
Phase of Trial: Phase I
Latest Information Update: 30 Apr 2018
At a glance
- Drugs Gemcitabine (Primary) ; WT1 peptide-loaded dendritic cell vaccine (Primary)
- Indications Biliary cancer; Pancreatic cancer
- Focus Adverse reactions
- 26 Apr 2018 Status changed from suspended to completed.
- 26 Jul 2014 Status changed from recruiting to suspended, as per University Hospital Medical Information Network - Japan record.
- 15 Jul 2011 New trial record